

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/574,101
Filing Date	March 8, 2007
First Named Inventor	Bernat VIDAL JUAN
Art Unit	1624
Examiner Name	V. BALASUBRAMANIAN

JUN 16 2009

PATENT PENDING

Attorney Docket Number

09605.0017-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,841,549 B1	01-11-2005	Asano et al.	
	2	US-2004/0176399 A1	09-09-2004	Elzein et al.	
	3	US-2003/0229106 A1	12-11-2003	Kalla et al.	
	4	US-2008/0275038 A1	11-06-2008	Vidal Juan et al.	
	5	US-2009/0023763 A1	01-22-2009	Vidal Juan et al.	
	6	US-2009/0042891 A1	02-12-2009	Vidal Juan et al.	
	7	US-5,916,905	06-09-1998	Carling et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	8	EP 1 308 441 A1	08-05-2003	Eisai Co. Ltd.		
	9	EP 1 221 444 A1	07-10-2002	Eisai Co. Ltd.		
	10	WO 07/039297 A1	04-12-2007	Laboratorios Almirall, SA		
	11	WO 07/017096 A1	02-15-2007	Almirall Prodesfarma, SA		
	12	WO 2005/100353 A1	10-27-2005	Almirall Prodesfarma, SA		
	13	WO 2005/070926 A1	08-04-2005	Novartis AG		
	14	WO 2005/042534 A2	05-12-2005	CV Therapeutics Inc.		
	15	WO 2005/040151 A1	05-06-2005	Fujisawa Pharmaceutical Co., Ltd.		
	16	WO 2005/040155 A1	05-06-2005	Almirall Prodesfarma, S.A.		
	17	WO 2005/021548 A2	03-10-2005	Adenosine Therapeutics, LLC		
	18	WO 2004/106337 A1	12-09-2004	CV Therapeutics Inc.		
	19	WO 2004/076450 A1	09-10-2004	J. Uriach Y Compania		
	20	WO 2004/030635 A2	04-15-2004	Targegen, Inc.		
	21	WO 2004/022540 A2	03-18-2004	Fujisawa Pharmaceutical Co., Ltd.		
	22	WO 03/082191 A2	10-09-2003	Merck & Co., Inc.		
	23	WO 03/068773 A1	08-21-2003	Glaxo Group Ltd.		
	24	WO 03/063800 A2	08-07-2003	King Pharmaceuticals Research and Development, Inc.		
	25	WO 03/042214 A2	05-22-2003	CV Therapeutics Inc.		

Examiner Signature	/Venkataraman Balasubramanian/	Date Considered	08/17/2009
--------------------	--------------------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /VB/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	09605.0017-00000
-------	---	----	---	------------------------	------------------

Complete if Known

Application Number	10/574,101
Filing Date	March 8, 2007
First Named Inventor	Bernat VIDAL JUAN
Art Unit	1624
Examiner Name	V. BALASUBRAMANIAN

	26	WO 03/002566 A1	01-09-2003	CV Therapeutics Inc.		
	27	WO 02/42298 A1	05-30-2002	Novartis AG		
	28	WO 02/14282 A1	02-21-2002	Eisai Co., Ltd.		Abst.
	29	WO 01/60350 A2	08-23-2001	CV Therapeutics, Inc.		
	30	WO 01/16134 A1	03-08-2001	Vanderbilt University		
	31	WO 01/02400 A1	01-11-2001	Eisai Co. Ltd.		Abst.
	32	WO 00/73307 A2	12-07-2000	University of Virginia Patent Foundation		
	33	WO 99/32448	07-01-1999	Amgen, Inc.		

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	34	Al-Masoudi, N.A.L. and Pfleiderer, W., "Nucleosides LIII" Syntheses and Reactions of 6,7-Dipyridylumazine and 2'-Deoxylumazine N-1 Nucleosides," <i>Pteridines</i> , 4(3):119-125 (1993).	
	35	CAPLUS English Abstract of journal article by Tarkhov, L.I. et al. Accession No. 2005:630607 (2005).	
	36	Derwent WPI, Abstract of WO 02/14282 A1, "New 2-aminopyridine compounds are adenosine receptor antagonists for treating e.g. constipation, irritable bowel syndrome, diabetes, asthma and Parkinson's disease." <i>02/21/2002</i> .	
	37	Feoktistov, I. and Biaggioni, I., "Adenosine A _{2B} Receptors," <i>Pharmacological Reviews</i> , 49(4):381-402 (1997).	
	38	International Search Report for International Application No. PCT/EP2006/009620 (WO 2007/039297 A1) dated January 9, 2007.	
	39	International Search Report for International Application No. PCT/EP2006/007318 (WO 2007/017096 A1) dated November 22, 2006.	
	40	International Search Report for Application No. PCT/EP2005/003818 dated July 21, 2005.	
	41	Restriction Requirement for co-pending Application No. 11/997,048, dated May 1, 2009.	
	42	Rusinov, L.V. et al. "Synthesis and Antiviral Activity of 2-Amino-3-Ethoxycarbonylpyrazine Derivatives," <i>Pharmaceutical Chemistry Journal</i> , 39(12):630-635 (2005).	
	43	Schurreit, T. "4-Hydroxy-2H-[1]benzopyran-2-one als Baustein zur Synthese von Bisbenzopyranopyridinen," <i>Archiv der Pharmazie</i> 320:500-506 (1987).	Abst.

Examiner Signature	Venkataraman Balasubramanian/	Date Considered	08/17/2009
--------------------	-------------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.